This “neuroendocrine prostate cancer” (NEPC) or CRPC-NE is a subtype of PC that develops mainly via neuroendocrine transdifferentiation of prostate adenocarcinoma in response to AR inhibition therapy. This evidence concerns the gene AR and prostate adenocarcinoma.